Takeaways
- Navepegritide increased annualized growth velocity at 52 weeks compared with placebo.
- Treatment improved skeletal alignment, including tibial-femoral angle and mechanical axis deviation.
- Health-related quality of life measures showed…
Navepegritide demonstrates growth velocity, skeletal alignment in children with achondroplasia
